Preliminary data shows that the inhibitor significantly mitigates morphine tolerance in a mouse study
Invention Summary:
Mu opioids such as morphine and fentanyl are commonly used for pain management but can lead to tolerance, addiction, and opioid use disorder. Current therapeutic solutions for these adverse conditions include buprenorphine, methadone for opioid addiction, and naloxone for reversing opioid overdoses. However, there are no pharmaceutical approaches to preventing opioid tolerance and addiction that are available for clinical use. Mechanisms underlying mu opioid actions, particularly their side‐effects such as tolerance and reward, are extremely complex and involve multiple distinct systems or diverse signaling pathways.
Researchers at Rutgers have identified an inhibitor that diminishes morphine tolerance and reward without compromising the analgesic effect of morphine. Their preliminary data in mice has demonstrated the role of the inhibitor’s target in the molecular pathway that allows for mitigation of the risk of opioid addiction and overdose.
Market Applications:
Medication to be used in combination with a mu opioid drug, such as morphine or fentanyl, which enables use of opioids with reduced side effects
Direct treatment for mu opioid side effects
Advantages:
First-in-class potential
Potential for widespread adoption and use
Intellectual Property & Development Status: Provisional application filed. Patent pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships, contact: marketingbd@research.rutgers.edu